Special Issue

Advances in Castration-Resistant Prostate Cancer Treatment

Message from the Guest Editors

The androgen receptor (AR) is a transcriptional factor and plays a predominant role in prostate cancer (PCa) pathology. Hence, most PCa therapies target AR, specifically the ligand-binding domain of AR. However, regrading androgen deprivation therapies (ADT), though initially successful, their efficacy is limited, and tumor recurrence occurs frequently, eventually leading to the progression of castration-resistant prostate cancer (CRPC). Consequently, there is an urgent clinical need to develop novel therapeutic strategies for the treatment of prostate cancer. This Special Issue provides an extensive overview of recent advances in the development of targeted therapy for prostate cancer treatment, along with new strategies in basic and translational research. Understanding the molecular intricacies of the AR signaling pathways involved in prostate cancer progression will aid the development of competent targeted therapies that can be translated to clinics.

Guest Editors

Dr. Eswar Shankar

Medical Oncology Division, Department of Internal Medicine, Wexner Medical Center, Ohio State University, 420 W 12th Ave, Columbus, OH 43210, USA

Dr. Balaji Chandrasekaran

Rangel College of Pharmacy, Texas A&M University, College Station, TX 77843, USA

Deadline for manuscript submissions

30 November 2025

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)